[go: up one dir, main page]

WO2002042426A3 - Carrier system for specific artery wall gene delivery - Google Patents

Carrier system for specific artery wall gene delivery Download PDF

Info

Publication number
WO2002042426A3
WO2002042426A3 PCT/US2001/047072 US0147072W WO0242426A3 WO 2002042426 A3 WO2002042426 A3 WO 2002042426A3 US 0147072 W US0147072 W US 0147072W WO 0242426 A3 WO0242426 A3 WO 0242426A3
Authority
WO
WIPO (PCT)
Prior art keywords
artery wall
carrier system
gene delivery
specific artery
wall gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/047072
Other languages
French (fr)
Other versions
WO2002042426A2 (en
Inventor
Lei Yu
Sung Wan Kim
Jae-Woon Nah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation Inc
Original Assignee
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation Inc filed Critical University of Utah Research Foundation Inc
Priority to AU2002241603A priority Critical patent/AU2002241603A1/en
Priority to US10/416,381 priority patent/US7264969B1/en
Publication of WO2002042426A2 publication Critical patent/WO2002042426A2/en
Publication of WO2002042426A3 publication Critical patent/WO2002042426A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

An artery wall binding peptide (AWBP) based on the artery wall cell-binding domain of apolipoprotein B-100 was conjugated to a cationic backbone configured for forming a complex with a nucleic acid to produce a composition that enhances gene transfer to artery wall cells. An illustrative cationic backbone is poly(ethylene glycol)-grafted-poly(L-lysine) (PEG-g-PLL). Methods of making and using the composition for gene transfer are also described.
PCT/US2001/047072 2000-11-10 2001-11-09 Carrier system for specific artery wall gene delivery Ceased WO2002042426A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002241603A AU2002241603A1 (en) 2000-11-10 2001-11-09 Carrier system for specific artery wall gene delivery
US10/416,381 US7264969B1 (en) 2000-11-10 2001-11-09 Carrier system for specific artery wall gene delivery

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24732000P 2000-11-10 2000-11-10
US60/247,320 2000-11-10

Publications (2)

Publication Number Publication Date
WO2002042426A2 WO2002042426A2 (en) 2002-05-30
WO2002042426A3 true WO2002042426A3 (en) 2002-10-17

Family

ID=22934463

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/047072 Ceased WO2002042426A2 (en) 2000-11-10 2001-11-09 Carrier system for specific artery wall gene delivery

Country Status (2)

Country Link
AU (1) AU2002241603A1 (en)
WO (1) WO2002042426A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111420068B (en) * 2019-11-13 2021-11-09 浙江大学 Polyethylene glycol-dendritic polylysine/anhydride-cisplatin compound and preparation method and application thereof

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105003A1 (en) 2001-04-05 2003-06-05 Jan Nilsson Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
SE0103754L (en) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptides from apolipoprotein B, use thereof immunization, method of diagnosis or therapeutic treatment of ischemic cardiovascular diseases, and pharmaceutical composition and vaccine containing such peptide
CA2460787A1 (en) 2001-09-28 2003-04-03 Esperion Therapeutics, Inc. Prevention and treatment of restenosis by local administration of drug
FR2835829B1 (en) * 2002-02-13 2007-09-14 Centre Nat Rech Scient NOVEL PROCESS FOR THE PREPARATION OF DNA OR PROTEIN BIOPUCES AND THEIR APPLICATIONS
EP1732383A4 (en) 2004-04-06 2007-05-02 Cedars Sinai Medical Center PREVENTION AND TREATMENT OF VASCULAR DISEASES WITH VIRUS VECTORS ASSOCIATED WITH RECOMBINANT ADENOVIRUS CODING APOLIPOPROTEIN A-I AND APOLIPOPROTEIN A-I MILANO
US20100028402A1 (en) * 2006-10-25 2010-02-04 Marina Dobrovolskaia Nanoparticle-based anticoagulant
GB0724253D0 (en) 2007-12-12 2008-01-30 Fermentas Uab Transfection reagent
US9856456B2 (en) 2009-10-12 2018-01-02 Thermo Fisher Scientific Baltics Uab Delivery agent
CN103501806A (en) 2010-11-12 2014-01-08 赛达斯西奈医疗中心 Immunomodulatory methods and systems for treating and/or preventing aneurysms
CA2817543A1 (en) 2010-11-12 2012-06-07 Cedars-Sinai Medical Center Immunomodulatory methods and systems for treatment and/or prevention of hypertension
CN112226207B (en) * 2020-10-28 2021-10-22 兰州大学 A kind of high stability solid-solid composite phase change material and preparation method thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NAH ET AL.: "Artery wall binding peptide-poly (ethylene glycol)-grafted-poly (L-Lysine)-based gene delivery to artery wall cells", JOURNAL OF CONTROLLED RELEASE, vol. 78, no. 1-3, January 2002 (2002-01-01), pages 273 - 284, XP002953705 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111420068B (en) * 2019-11-13 2021-11-09 浙江大学 Polyethylene glycol-dendritic polylysine/anhydride-cisplatin compound and preparation method and application thereof

Also Published As

Publication number Publication date
WO2002042426A2 (en) 2002-05-30
AU2002241603A1 (en) 2002-06-03

Similar Documents

Publication Publication Date Title
WO2002042426A3 (en) Carrier system for specific artery wall gene delivery
EP1541690A3 (en) Transfer of mRNA using polycationic compounds
DE50006269D1 (en) COMBINATIONS FOR THE INTRODUCTION OF NUCLEIC ACIDS IN CELLS
AU3999495A (en) Peptide nucleic acid conjugates
WO2004097017A3 (en) Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells
EP1808180A3 (en) Modified GP 100 and uses thereof
AU6097100A (en) Crosslinked dna condensate compositions and gene delivery methods
WO2000052155A3 (en) Recombination of insertion modified nucleic acids
AU6384196A (en) Recombinational cloning using engineered recombination sites
AU3246300A (en) Polypeptides having galactose oxidase activity and nucleic acids encoding same
AU4981101A (en) Subtilisin variants
MX9605716A (en) Methods and compositions for treatment of restenosis and cancer using ribozymes.
EP0999279A4 (en) Gene transfer method with the use of serum-free medium
WO2001090345A3 (en) Methods and compositions for enhancing the delivery of a nucleic acid to a cell
MXPA03002572A (en) Nucleotide sequences mediating male fertility and method of using same.
CY1105109T1 (en) PROCESS FOR THE PREPARATION OF LOW MOLECULAR WEIGHT POLYETHYLENE IMINE
AU3178499A (en) Transfer method for specific cellular localisation of nucleic acids
WO2000012732A3 (en) Organelle targeting sequences
WO2000042208A8 (en) Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
WO1997027276A3 (en) Nucleic acids encoding polypeptides having absidia lipase activity
EP1020529A3 (en) Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
WO2002094983A3 (en) Dna-antibody complexes to enhance gene transfer
WO2002077184A3 (en) Oligonucleotide conjugates
BR9814273A (en) Copolymers grafted as gene carriers
WO1998058055A3 (en) Antisense nucleic acids targeting hbv

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP